Register Login

ADC Therapeutics SA (ADCT)

(90% Positive) ADC Therapeutics SA (ADCT) Announces Enrollment Update for contained Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 7:58 p.m.

    📋 ADC Therapeutics SA (ADCT) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 08:37:42

    Event Type: Clinical Trial Update

    Event Details:

    ADC Therapeutics SA (ADCT) Announces Clinical Trial Update ADC Therapeutics SA (ADCT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: contained
    • Collaboration: ADC Therapeutics
      • anticipated in the forward - looking statements is contained in the "Risk Fac tors" section of the Company's Annual Report on Form 10 - K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements i nvo lve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, ac hievements or prospects expressed in or implied by such forward - looking statements. The Company cautions investors not to place undue reliance on the forward - looking statements contained in this docum ent. Forward - looking statements are based on our management’s beliefs and assumptions and on information currently available to our m anagement. No assurance can be given that such future results will be achieved. Such forward - looking statements contained in this presentation speak only as of the date of this presentation. The Com pany expressly disclaim any obligation or undertaking to update these forward - looking statements contained in this presentation to reflect any change in our expectations or any change in events, con ditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of a ny such forward - looking statements. The revenue and cash and cash equivalents figures are preliminary and unaudited and reflect the Company’s estimated financial re sults. In preparing this information, management made a number of complex and subjective judgments and estimates about the appropriateness of certain reported amounts and disclosures. The Com pan y’s actual financial results for the quarter and year ended December 31, 2025

    🔬 Clinical Development Pipeline (ADC Therapeutics SA):

    Product Type Development Stage Therapeutic Area Source
    Mosunetuzumab DRUG Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ClinicalTrials.gov
    Loncastuximab Tesirine DRUG Phase PHASE3 Relapsed Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Reference product intra-articular injection DEVICE Phase PHASE2 Knee Osteoarthritis ClinicalTrials.gov
    Epcoritamab DRUG Phase PHASE2 Large B-cell Lymphoma ClinicalTrials.gov
    Placebo OTHER Phase PHASE1 Heart ClinicalTrials.gov
    VS-041 DRUG Phase PHASE1 Heart ClinicalTrials.gov
    Oxaliplatin DRUG Phase PHASE3 Relapsed Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Gemcitabine DRUG Phase PHASE3 Relapsed Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Rituximab DRUG Phase PHASE3 Relapsed Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    CP-383 DRUG Phase PHASE1 Solid Tumor Malignancies ClinicalTrials.gov
    ADCT-602 BIOLOGICAL Phase PHASE1 Blasts 5 Percent or More of Bone Marrow Nucleated Cells ClinicalTrials.gov
    Loncastuximab tesirine and rituximab (Lonca-R) DRUG Phase PHASE1 Central Nervous System Lymphoma ClinicalTrials.gov
    Endoscopic Sleeve Gastroplasty - Belt DEVICE Approved Obesity ClinicalTrials.gov
    Endoscopic Sleeve Gastroplasty - Belt and Suspenders DEVICE Approved Obesity ClinicalTrials.gov
    Vincristine DRUG Phase PHASE2 Double-Expressor Lymphoma ClinicalTrials.gov
    Prednisone DRUG Phase PHASE2 Double-Expressor Lymphoma ClinicalTrials.gov
    Etoposide DRUG Phase PHASE2 Double-Expressor Lymphoma ClinicalTrials.gov
    Doxorubicin DRUG Phase PHASE2 Double-Expressor Lymphoma ClinicalTrials.gov
    Cyclophosphamide DRUG Phase PHASE2 Double-Expressor Lymphoma ClinicalTrials.gov
    Immune checkpoint inhibitor DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    DT-7012 DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    Obinutuzumab DRUG Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ClinicalTrials.gov
    Glofitamab DRUG Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ClinicalTrials.gov
    Polatuzumab Vedotin DRUG Phase PHASE1 B-Cell Non-Hodgkin Lymphoma ClinicalTrials.gov
    Loncastuximab Tesirine and Acalabrutinib DRUG Phase PHASE1 Chronic Lymphocytic Leukemia ClinicalTrials.gov
    Loncastuximab tesirine 75µg/Kg DRUG Phase PHASE2 Marginal Zone Lymphoma ClinicalTrials.gov
    Loncastuximab tesirine 150 µg/Kg DRUG Phase PHASE2 Marginal Zone Lymphoma ClinicalTrials.gov
    MEN1703 DRUG Phase PHASE2 Non-Hodgkin Lymphoma, B-cell ClinicalTrials.gov
    RVU120 DRUG Phase PHASE2 Advanced Solid Tumors ClinicalTrials.gov
    Ruxolitinib DRUG Phase PHASE2 Myelofibrosis ClinicalTrials.gov
    SNX-001 DRUG Phase PHASE1 Safety ClinicalTrials.gov
    CER-001 DRUG Phase PHASE2 Homozygous Familial Hypercholesterolemia ClinicalTrials.gov
    Core decompression/BMC implantation DRUG Phase PHASE2 Avascular Necrosis of Femur Head ClinicalTrials.gov
    Core decompression/PREOB® implantation DRUG Phase PHASE2 Avascular Necrosis of Femur Head ClinicalTrials.gov
    ADCT-301 DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    ADCT-601 DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    Camidanlumab tesirine DRUG Phase PHASE1 Hodgkin Lymphoma ClinicalTrials.gov
    ADCT-502 DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov
    ADCT-402 DRUG Phase PHASE1 Non-Hodgkin Lymphoma ClinicalTrials.gov
    Core decompression/placebo implantation DRUG Phase PHASE3 Osteonecrosis of the Femoral Head ClinicalTrials.gov
    Loncastuximab Tesirine and Durvalumab DRUG Phase PHASE1 Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Hylan G-F 20 DEVICE Phase PHASE3 Symptomatic Osteoarthritis of the Knee ClinicalTrials.gov
    JTA-004 DRUG Phase PHASE3 Symptomatic Osteoarthritis of the Knee ClinicalTrials.gov
    JTA-004 intra-articular injection DRUG Phase PHASE2 Knee Osteoarthritis ClinicalTrials.gov
    ALLOB® implantation DRUG Phase PHASE1 Long Bone Delayed-Union Fracture ClinicalTrials.gov
    ART24 BIOLOGICAL Phase PHASE1 Clostridium Difficile Infection Recurrence ClinicalTrials.gov
    Melphalan DRUG Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Cytarabine DRUG Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Carmustine DRUG Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Autologous Hematopoietic Stem Cell Transplantation PROCEDURE Phase PHASE1 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Diet BEHAVIORAL Approved Sleep Apnea Syndromes ClinicalTrials.gov
    Endomina- Endoscopic Sleeve Gastroplasty DEVICE Approved Sleep Apnea Syndromes ClinicalTrials.gov
    Idelalisib DRUG Phase PHASE2 Relapsed Follicular Lymphoma ClinicalTrials.gov
    RVU120(SEL120) DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Matching Placebo DRUG Phase PHASE1 Ulcerative Colitis ClinicalTrials.gov
    BT051 3200 mg DRUG Phase PHASE1 Ulcerative Colitis ClinicalTrials.gov
    BT051 800 mg DRUG Phase PHASE1 Ulcerative Colitis ClinicalTrials.gov
    BT051 200 mg DRUG Phase PHASE1 Ulcerative Colitis ClinicalTrials.gov
    Adacolumn DEVICE Approved Ulcerative Colitis ClinicalTrials.gov
    Oligonucleotides, Phosphorothioate DRUG Phase PHASE1 Immune System ClinicalTrials.gov
    Pembrolizumab BIOLOGICAL Phase PHASE1 Head and Neck Cancer Squamous Cell Carcinoma ClinicalTrials.gov
    Ibrutinib DRUG Phase PHASE1 Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Dexamethasone DRUG Phase PHASE2 Waldenstrom Macroglobulinemia ClinicalTrials.gov
    DT-9081 - expansion DRUG Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    DT-9081 - dose escalation DRUG Phase PHASE1 Solid Tumor, Adult ClinicalTrials.gov
    EVEROLIMUS DRUG Phase PHASE1 Hepatocellular Carcinoma (HCC) ClinicalTrials.gov
    CT-01 DRUG Phase PHASE1 Hepatocellular Carcinoma (HCC) ClinicalTrials.gov
    RVU120 (SEL120) DRUG Phase PHASE2 Low Risk Myelodysplastic Syndromes ClinicalTrials.gov
    AAV9 BBP-812 BIOLOGICAL Phase PHASE1 Canavan Disease ClinicalTrials.gov
    endomina® DEVICE Approved Diabetes Mellitus, Type 2 ClinicalTrials.gov
    ADCT-901 DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    Venetoclax DRUG Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ADC Therapeutics SA
    • Ticker Symbol: ADCT

Search

News categories